Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aprea Therapeutics Inc.

    NASDAQ: APRE · Real-Time Price · USD
    1.78
    -0.06 (-3.27%)
    At close: Jun 16, 2025, 3:59 PM
    1.77
    -0.56%
    After-hours: Jun 16, 2025, 04:04 PM EDT

    Aprea Therapeutics Statistics

    Share Statistics

    Aprea Therapeutics has 5.53M shares outstanding. The number of shares has increased by 1.14% in one year.

    Shares Outstanding

    n/a
    		 5.53M

    Shares Change (YoY)

    n/a
    		 1.14%

    Shares Change (QoQ)

    n/a
    		 1.05%

    Owned by Institutions (%)

    n/a
    		 37.7%

    Shares Floating

    n/a
    		 4.83M

    Failed to Deliver (FTD) Shares

    n/a
    		 753

    FTD / Avg. Volume

    n/a
    		 2.75%

    Short Selling Information

    The latest short interest is 73.65K, so 1.33% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 73.65K

    Short % of Shares Out

    n/a
    		 1.33%

    Short % of Float

    n/a
    		 1.51%

    Short Ratio (days to cover)

    n/a
    		 2.1

    Valuation Ratios

    The PE ratio is -1.4 and the forward PE ratio is -1.32. Aprea Therapeutics's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -1.4

    Forward PE

    n/a
    		 -1.32

    PS Ratio

    n/a
    		 12.06

    Forward PS

    n/a
    		 0.1

    PB Ratio

    n/a
    		 0.94

    P/FCF Ratio

    n/a
    		 -1.34

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Aprea Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.01, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 7.01

    Quick Ratio

    n/a
    		 7.01

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $187,822.62

    Profits Per Employee

    n/a
    		 $-1,619,838.88

    Employee Count

    n/a
    		 8

    Asset Turnover

    n/a
    		 0.06

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -56.92% in the last 52 weeks. The beta is 1.61, so Aprea Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.61

    52-Week Price Change

    n/a
    		 -56.92%

    50-Day Moving Average

    n/a
    		 1.7

    200-Day Moving Average

    n/a
    		 2.83

    Relative Strength Index (RSI)

    n/a
    		 52.86

    Average Volume (20 Days)

    n/a
    		 27,390

    Income Statement

    In the last 12 months, Aprea Therapeutics had revenue of 1.5M and earned -12.96M in profits. Earnings per share was -2.35.

    Revenue

    n/a
    		 1.5M

    Gross Profit

    n/a
    		 1.48M

    Operating Income

    n/a
    		 -14.32M

    Net Income

    n/a
    		 -12.96M

    EBITDA

    n/a
    		 -12.94M

    EBIT

    n/a
    		 -12.96M

    Earnings Per Share (EPS)

    n/a
    		 -2.35
    Full Income Statement

    Balance Sheet

    The company has 22.85M in cash and 0 in debt, giving a net cash position of 22.85M.

    Cash & Cash Equivalents

    n/a
    		 22.85M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -321.04M

    Total Assets

    n/a
    		 20.22M

    Working Capital

    n/a
    		 16.47M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -13.56M and capital expenditures -15.48K, giving a free cash flow of -13.57M.

    Operating Cash Flow

    n/a
    		 -13.56M

    Capital Expenditures

    n/a
    		 -15.48K

    Free Cash Flow

    n/a
    		 -13.57M

    FCF Per Share

    n/a
    		 -2.46
    Full Cash Flow Statement

    Margins

    Gross margin is 98.51%, with operating and profit margins of -953% and -862.43%.

    Gross Margin

    n/a
    		 98.51%

    Operating Margin

    n/a
    		 -953%

    Pretax Margin

    n/a
    		 -862.43%

    Profit Margin

    n/a
    		 -862.43%

    EBITDA Margin

    n/a
    		 -860.94%

    EBIT Margin

    n/a
    		 -953%

    FCF Margin

    n/a
    		 -903.26%

    Dividends & Yields

    APRE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for APRE is $15.5, which is 715.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $15.5

    Price Target Difference

    n/a
    		 715.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Feb 13, 2023. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Feb 13, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -22.74

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist